Ginkgo Bioworks Holdings, Inc.
DNA · NYSE
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $811,140 | $617,164 | $309,177 | $509,605 |
| - Cash | $111,065 | $203,566 | $312,420 | $561,572 |
| + Debt | $422,870 | $428,827 | $434,561 | $467,731 |
| Enterprise Value | $1,122,945 | $842,425 | $431,318 | $415,764 |
| Revenue | $38,837 | $49,604 | $48,318 | $43,847 |
| % Growth | -21.7% | 2.7% | 10.2% | – |
| Gross Profit | $26,035 | $34,782 | $36,271 | $34,225 |
| % Margin | 67% | 70.1% | 75.1% | 78.1% |
| EBITDA | -$66,586 | -$46,074 | -$68,329 | -$143,484 |
| % Margin | -171.4% | -92.9% | -141.4% | -327.2% |
| Net Income | -$80,755 | -$60,300 | -$90,957 | -$107,534 |
| % Margin | -207.9% | -121.6% | -188.2% | -245.2% |
| EPS Diluted | -1.45 | -1.1 | -1.68 | -2.07 |
| % Growth | -31.8% | 34.5% | 18.8% | – |
| Operating Cash Flow | -$31,606 | -$40,254 | -$51,521 | -$42,435 |
| Capital Expenditures | $0 | -$38 | -$7,622 | -$13,710 |
| Free Cash Flow | -$31,606 | -$40,292 | -$59,143 | -$56,145 |